Innovation | Novartis United States of America

Media Release
Oct 17, 2009
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Media Release
Nov 17, 2010
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
Media Release
Oct 21, 2010
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
Media Release
Sep 22, 2010
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Media Release
Dec 22, 2010
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
Media Release
Dec 06, 2010
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
Media Release
Nov 30, 2010
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
Media Release
Apr 11, 2011
Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
Media Release
Mar 08, 2011
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Media Release
Jan 10, 2011
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
Media Release
May 25, 2011
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Media Release
May 24, 2011
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour

‹ Previous page
1
…
28
29
30
31
32
33
34
…
49
› Next page